ABBV vs HCA

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

HCA Healthcare trades near its 52-week high with strong price momentum, up 37.9% over the past year and 225.1% over five years, reflecting sustained operational outperformance. The company delivered robust YoY earnings growth of 42.6%, supported by consistent quarterly beats—21 of the last 25 quarters—and accelerating revenue growth at 9.6%. Despite a premium valuation relative to some peers, HCA’s profitability metrics, including a 15.47% operating margin and 12.20% ROA, are industry-leading and justify the multiple. Analysts are aligned with a 'buy' recommendation and a $477.57 target price, implying modest upside, while insider selling remains limited in volume and likely routine.